Efficacy News and Research

RSS

Research provides novel insight into potential new therapeutic targets for triple-negative breast cancer

Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult to treat and aggressive form of the disease.

28 Oct 2015

Praziquantel treatment safe for pregnant women after first trimester

A study by Rhode Island Hospital researchers confirmed that a drug used to treat a disease afflicting millions of people in developing countries is safe to give pregnant women following their first trimester. The finding could prove critical to the care of pregnant women and lactating women with schistosomiasis, a disease caused by a parasitic worm, who were denied the drug out of concern for their health and the health of their fetuses.

28 Oct 2015

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

Environment can make all the difference in behavior - even at the cellular level. Scientists at the Virginia Tech Carilion Research Institute have discovered even a small shift in environmental factors can change how a cell in the immune system matures.

28 Oct 2015

Oral formulation of insulin shows promise in management of blood glucose in diabetic rats

An intestinal patch device containing insulin that can be swallowed in the form of a capsule, in development by researchers at University of California Santa Barbara, has demonstrated efficacy of blood glucose management in diabetic rats. This work is being presented Oct. 27 at the 2015 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Orlando, Fla. Oct. 25-29.

28 Oct 2015

Imlygic approved for treatment of melanoma lesions in the skin and lymph nodes

The U.S. Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes.

28 Oct 2015

Oxytocin treatment improves social, emotional and behavioral problems among young kids with autism

A five week treatment with the synthetic hormone oxytocin significantly improved social, emotional and behavioral issues among young children with autism, according to University of Sydney research published today in Molecular Psychiatry.

27 Oct 2015

New article reviews latest advances in magnetic particle tracking in cell therapy

A new article published in Regenerative Medicine reviews the latest advances in magnetic particle tracking in cell therapy, a potentially groundbreaking strategy in disease treatment and regenerative medicine.

27 Oct 2015

Ipsen, EpiVax partner to create next generation botulinum neurotoxin and TSI therapeutics

Ipsen and the US company EpiVax, Inc. today announced that they have completed a collaborative project that provides a novel approach for creating next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics.

27 Oct 2015

Novel method for examining small molecules may provide platform for new drug design

Most pharmaceutical drugs consist of tiny molecules, which target a class of proteins found on the surfaces of cell membranes. Studying these subtle interactions is essential for the design of effective drugs, but the task is extremely challenging.

26 Oct 2015

SAGE recommends pilot implementation of malaria vaccine to protect young children

The World Health Organization’s Strategic Advisory Group of Experts on Immunization (SAGE) recommended pilot projects to understand how to best use a vaccine that protects against malaria in young children.

26 Oct 2015

Strensiq approved for treatment of patients with juvenile-onset HPP

Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).

24 Oct 2015

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Amgen today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion recommending that IMLYGIC (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

23 Oct 2015

Early trial results in lung cancer

Results from early phase trials investigating different therapeutic agents in lung cancer patients were presented during the third Presidential Session at the European Cancer Congress in Vienna, Austria. Here we summarise two studies reported at the session.

22 Oct 2015

CML arterial adverse events rate dependent on TKI choice

The risk of major arterial adverse events in chronic myeloid leukaemia patients may significantly differ between tyrosine kinase inhibitors, suggests a meta-analysis published in Leukemia & Lymphoma.

22 Oct 2015

CV risk assessment essential for CML TKI trial design

The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology.

22 Oct 2015

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Eli Lilly and Company today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.

22 Oct 2015

Research provides leads for new strategies to develop HIV vaccine

Recent research has yielded new information about immune responses associated with--and potentially responsible for--protection from HIV infection, providing leads for new strategies to develop an HIV vaccine.

22 Oct 2015

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

An international team led by researchers from the Broad Institute of MIT and Harvard, the Harvard T.H. Chan School of Public Health, and Fred Hutchinson Cancer Research Center have used cutting edge genomic methods to uncover key biological insights that help explain the protective effects of the world's most advanced malaria vaccine candidate, RTS,S/AS01 (RTS,S).

22 Oct 2015

Coagadex now approved by FDA for patients with hereditary Factor X deficiency

The U.S. Food and Drug Administration today approved Coagadex, Coagulation Factor X (Human), for hereditary Factor X (10) deficiency. Until today's orphan drug approval, no specific coagulation factor replacement therapy was available for patients with hereditary Factor X deficiency.

21 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

Efficacy News and Research

Research provides novel insight into potential new therapeutic targets for triple-negative breast cancer

Praziquantel treatment safe for pregnant women after first trimester

Virginia Tech researchers study how specific cytokine influences gene expression patterns in T helper cells

Oral formulation of insulin shows promise in management of blood glucose in diabetic rats

Imlygic approved for treatment of melanoma lesions in the skin and lymph nodes

Oxytocin treatment improves social, emotional and behavioral problems among young kids with autism

New article reviews latest advances in magnetic particle tracking in cell therapy

Ipsen, EpiVax partner to create next generation botulinum neurotoxin and TSI therapeutics

Novel method for examining small molecules may provide platform for new drug design

SAGE recommends pilot implementation of malaria vaccine to protect young children

Strensiq approved for treatment of patients with juvenile-onset HPP

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Early trial results in lung cancer

CML arterial adverse events rate dependent on TKI choice

CV risk assessment essential for CML TKI trial design

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Research provides leads for new strategies to develop HIV vaccine

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

Coagadex now approved by FDA for patients with hereditary Factor X deficiency

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News